Laboratory of Mycobacterial Immunity and Pathogenesis,1 Tuberculosis Center, Public Health Research Institute, International Center for Public Health, Newark, New Jersey,3 Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland2
Received 11 February 2004/ Returned for modification 29 March 2004/ Accepted 11 June 2004
| ABSTRACT |
|---|
|
|
|---|
| TEXT |
|---|
|
|
|---|
To understand the differential activation of host immunity by CDC1551 and HN878 at the molecular level, human peripheral blood mononuclear cells isolated from healthy donors (12) were infected with either clinical isolate (9) at a multiplicity of infection (MOI) of 5:1 or stimulated at 1:50 with the total chloroform-methanol lipid extract from each strain (17). The responses to bacilli or their lipid products were compared in cells from the same donor. At 5 to 42 h, total cellular RNA was isolated with TriReagent (Molecular Research Center, Inc.), reverse transcribed into cDNA, and hybridized to gene-specific cDNA spotted on GEArray Q series membranes (SuperArray, Bethesda, Md.). Two commercial 96-gene arrays were used: human inflammatory cytokine receptors (catalog no. HS-015N-12) and common cytokines (catalog no. HS-003N12). The ScanAlyze 2 program was used for image analysis, and a GEArrayAnalyzer was used to process the raw data. Both CDC1551 and HN878 induced up-regulation of a large number of cytokines, chemokines, and their receptor genes relative to the levels observed in uninfected cells.
Host cell genes differentially induced (more than twofold) by the two strains after infection or lipid stimulation are shown in Table 1. The proinflammatory cytokines interleukin-1
(IL-1
), IL-10, and IL-12
/ß, the chemokine macrophage inflammatory protein 3
(MIP-3
), and the chemokine receptor CCR7 genes were significantly and repeatedly (from donor to donor) up-regulated in cells infected with CDC1551 relative to the levels observed in HN878-infected cells. In contrast, cytokines associated with macrophage deactivation (IL-13 and IL-11) and humoral immunity (IL-4), IL-17, type I interferon genes, and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and certain growth factor genes were significantly up-regulated in HN878-infected cells compared to their levels in cells infected with CDC1551. Human monocytes stimulated with lipid extracts from the two strains showed a similar differential pattern of up-regulation of cytokine and chemokine genes. Differential up-regulation in response to HN878 lipids was noted for IL-13, TARC, CCR5, vascular endothelial growth factor (VEGF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNAs while IL-12ß, MIP-3
, and FAS ligand (CD95) and other Th1 immunity-associated genes were preferentially up-regulated in CDC1551 lipid-exposed cells. A semiquantitative reverse transcription (RT)-PCR assay confirmed the differential gene expression for IL-12ß (significantly [P = 0.05] higher in CDC1551-infected cells than in HN878-infected cells), IL-13 and VEGF (significantly [P = 0.04 and P = 0.004, respectively] higher for HN878 stimulation than for CDC1551 stimulation). The similarity of the lipid-induced gene profiles to the profiles of genes up-regulated by infection with viable bacilli suggested that the lipid components of the organisms confer the differential gene activation observed during monocyte infection.
|
, TRAIL, VEGF, IL-12, and TNF-
protein production in response to CDC1551 and HN878 infection. Supernatants from monocytes infected at MOIs of 1:1 and 5:1 and/or stimulated at 1:50 with total lipid extracts were assayed with commercial enzyme-linked immunosorbent assay (ELISA) kits (Endogen, Boston, Mass., and R&D Systems, Inc.). Bacilli or their lipid products were compared in cells from the same donor. At all of the time points analyzed, the MIP-3
concentration induced by CDC1551 was higher than that induced by HN878, with a significant (P < 0.05) difference at 5 h postinfection (Fig. 1A). TRAIL induction, measured at 24 h after infection, was significantly (P < 0.0001) elevated in HN878-infected cells (Fig. 1B). Maximal VEGF induction was detected on day 3 postinfection, and the levels induced were significantly (P = 0.004) higher for HN878-infected cells (Fig. 1C). HN878 induced significantly lower levels of IL-12 than did CDC1551 at 24 and 48 h (P
0.006) (Fig. 2A) and significantly lower levels of TNF-
at 24 h (P = 0.01) (Fig. 2B). We next examined the effect of total lipid extracts from HN878 and CDC1551 on cytokine induction. Maximum levels of TNF-
and IL-12 were detected at 24 and 48 h, respectively. Lipid extracts from HN878 elicited lower levels of TNF-
(P < 0.05) compared to levels induced by lipid extracts from CDC1551 (Fig. 2C, insert). IL-12 levels were significantly lower for lipids from HN878 than for CDC1551 at both of the time points analyzed (P < 0.001) (Fig. 2C). Thus, the lipid extracts appeared to impart the differential chemokines-cytokine protein response observed during monocyte infection.
|
|
cytokine levels over 4 days of infection (Fig. 2A and B). W4, W10, and 210, similar to HN878, induced significantly lower levels of IL-12 (P
0.05) at both 24 and 48 h postinfection, and TNF-
levels were found to be significantly lower than those of CDC1551 at 24 h postinfection (P = 0.008 for W4). In contrast, NHN5 cytokine induction was comparable to that of CDC1551. Intracellular replication rates could not account for these differences (24 h for HN878, 210, CDC1551, and NHN5 and 30 to 33 h for W4 and W10, respectively). Rather, the strains segregated according to their relatedness to the W/Beijing family of strains as determined by restriction fragment length polymorphism. Consistent with the cytokine responses to infection, lipid extracts from the W/Beijing strains (HN878 and W4) induced significantly (P < 0.05) lower levels of TNF-
and IL-12 than did those from non-W/Beijing strains (CDC151 and NHN5) (Fig. 2C). Our results suggest that certain members of the highly pathogenic W/Beijing family of M. tuberculosis strains produce lipids that fail to efficiently induce the cytokine-dependent Th1-type protective immune response. In the infected host this failure would ultimately result in delayed or impaired protective immunity, leading to more severe disease. These findings are consistent with previous reports associating members of the W/Beijing family of strains with multidrug-resistant outbreaks (6, 19, 21), relapse (8), and global spread (4). Our results may also explain the increased pathogenicity (reduced host survival) seen in mice infected with HN878 (11). Mycobacterial lipids have been shown to participate in both inhibitory and stimulatory signaling, as well as in granuloma formation (3, 15, 16).
Macrophage activation to a protective phenotype depends on TNF-
and gamma interferon produced by activated Th1-type lymphocytes. Less known is the alternative activation of macrophages trigged by IL-4 and IL-13. These cytokines produced during the Th2-type response (7) appear to deactivate phagocytes, inducing phenotypic changes that are different from those induced by IL-10. The alternative activation of macrophages has been studied most extensively in parasitic infection. Stimulation of macrophages with IL-4 and IL-13 contributes to the susceptibility of mice to infection with Leishmania major by reducing classical macrophage activation and suppressing the Th1 response (7). Furthermore, it has been shown that expression of the alternative activation pathway in the later stages of infection of mice with Trypanosoma brucei is required for establishment of the chronic phases of the disease (1, 13).
Our observation that W/Beijing M. tuberculosis isolates can induce alternative macrophage activation has not been reported before, probably because most investigators have used H37Rv for their studies on the macrophage response to infection. Nau et al. (14) showed that M. tuberculosis induced little IL-12 and IL-15 relative to other organisms and also suppressed IL-12 production by cells exposed to Escherichia coli. Our data suggest that the virulence of the W/Beijing family of strains may, at least in part, be attributed to the ability of their lipids to subvert the host's protective immune response in association with suboptimal IL-12 production.
| ACKNOWLEDGMENTS |
|---|
This work was supported by Public Health Service grants AI-54361 and AI-22616 from the National Institutes of Health to G.K.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| 1. | Baetselier, P. D., B. Namangala, W. Noel, L. Brys, E. Pays, and A. Beschin. 2001. Alternative versus classical macrophage activation during experimental African trypanosomiasis. Int. J. Parasitol. 31:575-587.[Medline] |
| 2. | Barnes, P. F., Z. Yang, S. Preston-Martin, J. M. Pogoda, B. E. Jones, M. Otaya, K. D. Eisenach, L. Knowles, S. Harvey, and M. D. Cave. 1997. Patterns of tuberculosis transmission in central Los Angeles. JAMA 278:1159-1163.[Abstract] |
| 3. | Behling, C. A., R. L. Perez, M. R. Kidd, G. W. Staton, Jr., and R. L. Hunter. 1993. Induction of pulmonary granulomas, macrophage procoagulant activity, and tumor necrosis factor-alpha by trehalose glycolipids. Ann. Clin. Lab. Sci. 23:256-266.[Abstract] |
| 4. | Bifani, P. J., B. Mathema, N. E. Kurepina, and B. N. Kreiswirth. 2002. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol. 10:45-52.[CrossRef][Medline] |
| 5. | Bifani, P. J., B. Mathema, Z. Liu, S. L. Moghazeh, B. Shopsin, B. Tempalski, J. Driscol, R. Frothingham, J. M. Musser, P. Alcabes, and B. N. Kreiswirth. 1999. Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology. JAMA 282:2321-2327. |
| 6. | Bifani, P. J., B. B. Plikaytis, V. Kapur, K. Stockbauer, X. Pan, M. L. Lutfey, S. L. Moghazeh, W. Eisner, T. M. Daniel, M. H. Kaplan, J. T. Crawford, J. M. Musser, and B. N. Kreiswirth. 1996. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 275:452-457.[Abstract] |
| 7. | Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3:23-35.[CrossRef][Medline] |
| 8. | Lan, N. T., H. T. Lien, B. Tung le, M. W. Borgdorff, K. Kremer, and D. van Soolingen. 2003. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg. Infect. Dis. 9:1633-1635.[Medline] |
| 9. | Laochumroonvorapong, P., J. Wang, C. C. Liu, W. Ye, A. L. Moreira, K. B. Elkon, V. H. Freedman, and G. Kaplan. 1997. Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice. Infect. Immun. 65:127-132.[Abstract] |
| 10. | Manca, C., L. Tsenova, C. E. Barry III, A. Bergtold, S. Freeman, P. A. Haslett, J. M. Musser, V. H. Freedman, and G. Kaplan. 1999. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J. Immunol. 162:6740-6746. |
| 11. | Manca, C., L. Tsenova, A. Bergtold, S. Freeman, M. Tovey, J. M. Musser, C. E. Barry III, V. H. Freedman, and G. Kaplan. 2001. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN- /ß. Proc. Natl. Acad. Sci. USA 98:5752-5757. |
| 12. | Molloy, A., P. A. Meyn, K. D. Smith, and G. Kaplan. 1993. Recognition and destruction of Bacillus Calmette-Guérin-infected human monocytes. J. Exp. Med. 177:1691-1698. |
| 13. | Namangala, B., P. De Baetselier, W. Noel, L. Brys, and A. Beschin. 2001. Alternative versus classical macrophage activation during experimental African trypanosomiasis. J. Leukoc. Biol. 69:387-396. |
| 14. | Nau, G. J., J. F. Richmond, A. Schlesinger, E. G. Jennings, E. S. Lander, and R. A. Young. 2002. Human macrophage activation programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. USA 99:1503-1508. |
| 15. | Sibley, L. D., L. B. Adams, and J. L. Krahenbuhl. 1990. Inhibition of interferon-gamma-mediated activation in mouse macrophages treated with lipoarabinomannan. Clin. Exp. Immunol. 80:141-148.[Medline] |
| 16. | Sibley, L. D., S. W. Hunter, P. J. Brennan, and J. L. Krahenbuhl. 1988. Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Infect. Immun. 56:1232-1236. |
| 17. | Slayden, R. A., and C. Barry III. 2001. Analysis of the lipids of Mycobacterium tuberculosis, p. 229-245. In T. P. N. G. Stoker (ed.), Mycobacterium tuberculosis protocols. Humana Press, Totowa, N.J. |
| 18. | Sreevatsan, S., X. Pan, K. E. Stockbauer, N. D. Connell, B. N. Kreiswirth, T. S. Whittam, and J. M. Musser. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl. Acad. Sci. USA 94:9869-9874. |
| 19. | Toungoussova, O. S., A. Mariandyshev, G. Bjune, P. Sandven, and D. A. Caugant. 2003. Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates in the Archangel prison in Russia: predominance of the W-Beijing clone family. Clin. Infect. Dis. 37:665-672.[CrossRef][Medline] |
| 20. | Valway, S. E., M. P. Sanchez, T. F. Shinnick, I. Orme, T. Agerton, D. Hoy, J. S. Jones, H. Westmoreland, and I. M. Onorato. 1998. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N. Engl. J. Med. 338:633-639. |
| 21. | van Rie, A., R. M. Warren, N. Beyers, R. P. Gie, C. N. Classen, M. Richardson, S. L. Sampson, T. C. Victor, and P. D. van Helden. 1999. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling "strain W" among noninstitutionalized, human immunodeficiency virus-seronegative patients. J. Infect. Dis. 180:1608-1615.[CrossRef][Medline] |
| 22. | Yang, Z., P. F. Barnes, F. Chaves, K. D. Eisenach, S. E. Weis, J. H. Bates, and M. D. Cave. 1998. Diversity of DNA fingerprints of Mycobacterium tuberculosis isolates in the United States. J. Clin. Microbiol. 36:1003-1007. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|